Compare Stocks: ELOX, PALI, GLAS, and ACOG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.74 -4.9%	$8.93	$4.50 ▼ $10.14	$200.14M	2.32	102,603 shs	48,323 shs
ELOX Eloxx Pharmaceuticals	$13.45 +1.9%	$15.34	$8.20 ▼ $23.40	$53.28M	-1960.42	25,648 shs	13,988 shs
GLAS Glass House Brands	$2.18 -4.4%	$6.17	$1.67 ▼ $13.93	$211.48M	N/A	2.57 million shs	1.40 million shs
PALI Palisade Bio	$1.16 -2.5%	$1.65	$1.10 ▼ $2.86	$207.38M	1.61	2.91 million shs	3.09 million shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	-4.90%	+4.80%	-2.89%	+5.56%	+33.03%
ELOX Eloxx Pharmaceuticals	+1.89%	+5.08%	-12.15%	-22.83%	+∞
GLAS Glass House Brands	-4.72%	+2.59%	-60.90%	-77.33%	+217,999,900.00%
PALI Palisade Bio	-2.52%	-12.78%	-14.07%	-38.79%	-45.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.74 -4.9%	$8.93	$4.50 ▼ $10.14	$200.14M	2.32	102,603 shs	48,323 shs
ELOX Eloxx Pharmaceuticals	$13.45 +1.9%	$15.34	$8.20 ▼ $23.40	$53.28M	-1960.42	25,648 shs	13,988 shs
GLAS Glass House Brands	$2.18 -4.4%	$6.17	$1.67 ▼ $13.93	$211.48M	N/A	2.57 million shs	1.40 million shs
PALI Palisade Bio	$1.16 -2.5%	$1.65	$1.10 ▼ $2.86	$207.38M	1.61	2.91 million shs	3.09 million shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	-4.90%	+4.80%	-2.89%	+5.56%	+33.03%
ELOX Eloxx Pharmaceuticals	+1.89%	+5.08%	-12.15%	-22.83%	+∞
GLAS Glass House Brands	-4.72%	+2.59%	-60.90%	-77.33%	+217,999,900.00%
PALI Palisade Bio	-2.52%	-12.78%	-14.07%	-38.79%	-45.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$18.00	105.95% Upside
ELOX Eloxx Pharmaceuticals	2.86	Moderate Buy	$37.33	177.57% Upside
GLAS Glass House Brands	2.00	Hold	$11.00	404.59% Upside
PALI Palisade Bio	3.00	Buy	$9.29	700.49% Upside

Current Analyst Ratings Breakdown

Latest ELOX, PALI, GLAS, and ACOG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$43.00 ➝ $40.00
10/21/2026	PALI Palisade Bio	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/20/2026	GLAS Glass House Brands	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$7.00
10/16/2026	ELOX Eloxx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/15/2026	ELOX Eloxx Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight
10/13/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
10/12/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/8/2026	PALI Palisade Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
10/8/2026	PALI Palisade Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
9/23/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target	Outperform	$32.00

(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	$15.26M	12.47	N/A	N/A	$2.88 per share	3.03
ELOX Eloxx Pharmaceuticals	$6.36M	8.54	N/A	N/A	($85.17) per share	-0.16
GLAS Glass House Brands	$181.98M	1.11	N/A	N/A	N/A	∞
PALI Palisade Bio	$500K	404.31	N/A	N/A	$0.87 per share	1.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$20.67M	-$1.10	N/A	N/A	N/A	-153.61%	-54.60%	-43.47%	11/12/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	-$29.66M	-$0.76	N/A	N/A	N/A	-31.68%	-60.92%	-15.69%	N/A
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)

Latest ELOX, PALI, GLAS, and ACOG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ACOG Alpha Cognition	-$0.33	N/A	N/A	N/A	$7.04 million	N/A
11/9/2026	Q3 2026	PALI Palisade Bio	-$0.06	N/A	N/A	N/A	$0.47 million	N/A
8/13/2026	Q2 2026	ACOG Alpha Cognition	-$0.3921	-$0.40	-$0.0079	-$0.40	$4.38 million	$6.00 million
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	9.03	8.04
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
GLAS Glass House Brands	0.77	1.33	0.70
PALI Palisade Bio	N/A	24.26	24.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
ELOX Eloxx Pharmaceuticals	2.90%
GLAS Glass House Brands	N/A
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	8.60%
ELOX Eloxx Pharmaceuticals	25.90%
GLAS Glass House Brands	N/A
PALI Palisade Bio	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	71	21.78 million	19.91 million	Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
GLAS Glass House Brands	357	92.75 million	N/A	Optionable
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable

ELOX, PALI, GLAS, and ACOG Headlines

Recent News About These Companies

Palisade Doses First Patient In Phase 2b Ulcerative Colitis Trial; Data Expected Q4 2027

October 29 at 3:33 AM | rttnews.com

Palisade Bio doses first patient in Phase 2b ulcerative colitis trial

October 28 at 10:32 PM | streetinsider.com

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

October 28 at 8:32 AM | globenewswire.com

Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.29

October 28 at 4:28 AM | marketbeat.com

Analyzing Theravance Biopharma (NASDAQ:TBPH) & Palisade Bio (NASDAQ:PALI)

October 28 at 2:29 AM | americanbankingnews.com

Palisade Bio, Inc. Presents Clinical and Translational Findings for Pali-2108 in Inflammatory Bowel Disease At Ueg Week 2026

October 22, 2026 | marketscreener.comM

Oppenheimer Remains a Buy on Palisade Bio (PALI)

October 22, 2026 | theglobeandmail.com

Julien E. Capers Files Form 3 Reporting No Holdings at Palisade Bio as of October 19, 2026

October 22, 2026 | kalkinemedia.comK

Palisade Bio Advances ASCENTRA-UC Trial, PALI-2108 Moves Deeper Into Ulcerative Colitis Market

October 21, 2026 | tipranks.com

Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease

October 20, 2026 | rttnews.com

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

October 20, 2026 | globenewswire.com

Palisade Bio (NASDAQ:PALI) Downgraded by Wall Street Zen to "Sell"

October 17, 2026 | marketbeat.com

Palisade Bio, Inc. Presents New Clinical, Pharmacokinetic, Pharmacodynamic And Mechanistic Data Strengthening Phase 2 Rationale For PALI-2108 In Ulcerative Colitis And Crohn?s ...

October 13, 2026 | marketscreener.comM

Palisade Bio's (PALI) "Buy" Rating Reiterated at HC Wainwright

October 13, 2026 | marketbeat.com

Palisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel Disease

October 12, 2026 | rttnews.com

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s ...

October 12, 2026 | markets.businessinsider.com

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

October 12, 2026 | globenewswire.com

Palisade Bio (NASDAQ:PALI) Raised to Moderate Buy at Raymond James Financial

October 10, 2026 | marketbeat.com

Raymond James initiates coverage of Palisade Bio with outperform

October 9, 2026 | msn.com

Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts

October 3, 2026 | marketbeat.com

Palisade Bio, Inc. Announces Pali-2108 to Be Featured in Four Presentations At United European Gastroenterology Week 2026

September 30, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, PALI, GLAS, and ACOG Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.74 -0.45 (-4.90%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$8.72 -0.02 (-0.17%)

As of 10/30/2026 07:30 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Eloxx Pharmaceuticals NASDAQ:ELOX

$13.45 +0.25 (+1.89%)

As of 10/30/2026 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Glass House Brands NYSE:GLAS

$2.18 -0.10 (-4.39%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$2.20 +0.02 (+1.15%)

As of 10/30/2026 07:58 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Palisade Bio NASDAQ:PALI

$1.16 -0.03 (-2.52%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$1.16 +0.00 (+0.34%)

As of 10/30/2026 07:30 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, PALI, GLAS, and ACOG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, PALI, GLAS, and ACOG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, PALI, GLAS, and ACOG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, PALI, GLAS, and ACOG Company Descriptions

Alpha Cognition NASDAQ:ACOG

Eloxx Pharmaceuticals NASDAQ:ELOX

Glass House Brands NYSE:GLAS

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, PALI, GLAS, and ACOG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, PALI, GLAS, and ACOG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, PALI, GLAS, and ACOG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, PALI, GLAS, and ACOG Company Descriptions

Alpha Cognition NASDAQ:ACOG

Eloxx Pharmaceuticals NASDAQ:ELOX

Glass House Brands NYSE:GLAS

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools